385 related articles for article (PubMed ID: 25466251)
1. Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes.
Gkogkas CG; Khoutorsky A; Cao R; Jafarnejad SM; Prager-Khoutorsky M; Giannakas N; Kaminari A; Fragkouli A; Nader K; Price TJ; Konicek BW; Graff JR; Tzinia AK; Lacaille JC; Sonenberg N
Cell Rep; 2014 Dec; 9(5):1742-1755. PubMed ID: 25466251
[TBL] [Abstract][Full Text] [Related]
2. Reducing eIF4E-eIF4G interactions restores the balance between protein synthesis and actin dynamics in fragile X syndrome model mice.
Santini E; Huynh TN; Longo F; Koo SY; Mojica E; D'Andrea L; Bagni C; Klann E
Sci Signal; 2017 Nov; 10(504):. PubMed ID: 29114037
[TBL] [Abstract][Full Text] [Related]
3. Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.
Han K; Chen H; Gennarino VA; Richman R; Lu HC; Zoghbi HY
Hum Mol Genet; 2015 Apr; 24(7):1813-23. PubMed ID: 25432536
[TBL] [Abstract][Full Text] [Related]
4. Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome.
Maurin T; Melancia F; Jarjat M; Castro L; Costa L; Delhaye S; Khayachi A; Castagnola S; Mota E; Di Giorgio A; Servadio M; Drozd M; Poupon G; Schiavi S; Sardone L; Azoulay S; Ciranna L; Martin S; Vincent P; Trezza V; Bardoni B
Cereb Cortex; 2019 Jul; 29(8):3241-3252. PubMed ID: 30137253
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome.
Lovelace JW; Wen TH; Reinhard S; Hsu MS; Sidhu H; Ethell IM; Binder DK; Razak KA
Neurobiol Dis; 2016 May; 89():126-35. PubMed ID: 26850918
[TBL] [Abstract][Full Text] [Related]
6. Research delves into role of key proteins in fragile X syndrome: study explores relationship between enzymes, FXS symptoms; identifies candidate drug for targeted treatment.
Levenson D
Am J Med Genet A; 2015 Mar; 167A(3):ix. PubMed ID: 25691428
[No Abstract] [Full Text] [Related]
7. Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome.
Su T; Fan HX; Jiang T; Sun WW; Den WY; Gao MM; Chen SQ; Zhao QH; Yi YH
Psychopharmacology (Berl); 2011 May; 215(2):291-300. PubMed ID: 21181121
[TBL] [Abstract][Full Text] [Related]
8. Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model.
Sidhu H; Dansie LE; Hickmott PW; Ethell DW; Ethell IM
J Neurosci; 2014 Jul; 34(30):9867-79. PubMed ID: 25057190
[TBL] [Abstract][Full Text] [Related]
9. Differential translation and fragile X syndrome.
Vanderklish PW; Edelman GM
Genes Brain Behav; 2005 Aug; 4(6):360-84. PubMed ID: 16098135
[TBL] [Abstract][Full Text] [Related]
10. Reversal of ultrasonic vocalization deficits in a mouse model of Fragile X Syndrome with minocycline treatment or genetic reduction of MMP-9.
Toledo MA; Wen TH; Binder DK; Ethell IM; Razak KA
Behav Brain Res; 2019 Oct; 372():112068. PubMed ID: 31271818
[TBL] [Abstract][Full Text] [Related]
11. Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation mice.
Iliff AJ; Renoux AJ; Krans A; Usdin K; Sutton MA; Todd PK
Hum Mol Genet; 2013 Mar; 22(6):1180-92. PubMed ID: 23250915
[TBL] [Abstract][Full Text] [Related]
12. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.
Henderson C; Wijetunge L; Kinoshita MN; Shumway M; Hammond RS; Postma FR; Brynczka C; Rush R; Thomas A; Paylor R; Warren ST; Vanderklish PW; Kind PC; Carpenter RL; Bear MF; Healy AM
Sci Transl Med; 2012 Sep; 4(152):152ra128. PubMed ID: 22993295
[TBL] [Abstract][Full Text] [Related]
13. Metformin ameliorates core deficits in a mouse model of fragile X syndrome.
Gantois I; Khoutorsky A; Popic J; Aguilar-Valles A; Freemantle E; Cao R; Sharma V; Pooters T; Nagpal A; Skalecka A; Truong VT; Wiebe S; Groves IA; Jafarnejad SM; Chapat C; McCullagh EA; Gamache K; Nader K; Lacaille JC; Gkogkas CG; Sonenberg N
Nat Med; 2017 Jun; 23(6):674-677. PubMed ID: 28504725
[TBL] [Abstract][Full Text] [Related]
14. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model.
Bilousova TV; Dansie L; Ngo M; Aye J; Charles JR; Ethell DW; Ethell IM
J Med Genet; 2009 Feb; 46(2):94-102. PubMed ID: 18835858
[TBL] [Abstract][Full Text] [Related]
15. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice.
Bhattacharya A; Kaphzan H; Alvarez-Dieppa AC; Murphy JP; Pierre P; Klann E
Neuron; 2012 Oct; 76(2):325-37. PubMed ID: 23083736
[TBL] [Abstract][Full Text] [Related]
16. Genetic reduction of MMP-9 in the Fmr1 KO mouse partially rescues prepulse inhibition of acoustic startle response.
Kokash J; Alderson EM; Reinhard SM; Crawford CA; Binder DK; Ethell IM; Razak KA
Brain Res; 2019 Sep; 1719():24-29. PubMed ID: 31128097
[TBL] [Abstract][Full Text] [Related]
17. Deletion of Fmr1 in parvalbumin-expressing neurons results in dysregulated translation and selective behavioral deficits associated with fragile X syndrome.
Kalinowska M; van der Lei MB; Kitiashvili M; Mamcarz M; Oliveira MM; Longo F; Klann E
Mol Autism; 2022 Jun; 13(1):29. PubMed ID: 35768828
[TBL] [Abstract][Full Text] [Related]
18. The small GTPase Arf6 is dysregulated in a mouse model for fragile X syndrome.
Briševac D; Scholz R; Du D; Elagabani MN; Köhr G; Kornau HC
J Neurochem; 2021 May; 157(3):666-683. PubMed ID: 33125726
[TBL] [Abstract][Full Text] [Related]
19. How dendritic spines shape is determined by MMP-9 activity in FXS.
Dziembowska M
Int Rev Neurobiol; 2023; 173():171-185. PubMed ID: 37993177
[TBL] [Abstract][Full Text] [Related]
20. Reversal of activity-mediated spine dynamics and learning impairment in a mouse model of Fragile X syndrome.
Boda B; Mendez P; Boury-Jamot B; Magara F; Muller D
Eur J Neurosci; 2014 Apr; 39(7):1130-7. PubMed ID: 24712992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
